Fig. 1From: A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosisStudy design. The four stages of the study design are shown in sequence along with the sample sizes of each of the trial cohorts utilized in the study. DB double-blind, OL open-label; RRMS relapsing-remitting multiple sclerosisBack to article page